These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 27593504

  • 1. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.
    Vestbo J, Leather D, Diar Bakerly N, New J, Gibson JM, McCorkindale S, Collier S, Crawford J, Frith L, Harvey C, Svedsater H, Woodcock A, Salford Lung Study Investigators.
    N Engl J Med; 2016 Sep 29; 375(13):1253-60. PubMed ID: 27593504
    [Abstract] [Full Text] [Related]

  • 2. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM.
    Lancet Respir Med; 2013 May 29; 1(3):210-23. PubMed ID: 24429127
    [Abstract] [Full Text] [Related]

  • 3. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C.
    Respir Med; 2017 Feb 29; 123():8-17. PubMed ID: 28137501
    [Abstract] [Full Text] [Related]

  • 4. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
    Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ, IMPACT Investigators.
    N Engl J Med; 2018 May 03; 378(18):1671-1680. PubMed ID: 29668352
    [Abstract] [Full Text] [Related]

  • 5. Benefit and safety of fluticasone furoate/vilanterol in the Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD) according to baseline patient characteristics and treatment subgroups.
    Bakerly ND, Woodcock A, Collier S, Leather DA, New JP, Crawford J, Harvey C, Vestbo J, Boucot I.
    Respir Med; 2019 Feb 03; 147():58-65. PubMed ID: 30704700
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT, Feldman G, Korenblat P, LaForce CF, Locantore N, Pistolesi M, Watkins ML, Crim C, Martinez FJ.
    Respir Med; 2014 Aug 03; 108(8):1171-9. PubMed ID: 24998880
    [Abstract] [Full Text] [Related]

  • 7. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
    Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID.
    Lancet Respir Med; 2015 Jun 03; 3(6):435-42. PubMed ID: 25878028
    [Abstract] [Full Text] [Related]

  • 8. Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease.
    McKeage K.
    Drugs; 2014 Sep 03; 74(13):1509-22. PubMed ID: 25074268
    [Abstract] [Full Text] [Related]

  • 9. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug 03; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 10. A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD.
    Rodrigo GJ, Neffen H.
    Pulm Pharmacol Ther; 2017 Feb 03; 42():1-6. PubMed ID: 27864038
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.
    Woodcock A, Vestbo J, Bakerly ND, New J, Gibson JM, McCorkindale S, Jones R, Collier S, Lay-Flurrie J, Frith L, Jacques L, Fletcher JL, Harvey C, Svedsater H, Leather D, Salford Lung Study Investigators.
    Lancet; 2017 Nov 18; 390(10109):2247-2255. PubMed ID: 28903864
    [Abstract] [Full Text] [Related]

  • 12. Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.
    Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PM.
    Respir Med; 2013 Apr 18; 107(4):550-9. PubMed ID: 23332861
    [Abstract] [Full Text] [Related]

  • 13. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD.
    Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM.
    Ann Am Thorac Soc; 2015 Jan 18; 12(1):27-34. PubMed ID: 25490706
    [Abstract] [Full Text] [Related]

  • 14. A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.
    Bhatt SP, Dransfield MT, Cockcroft JR, Wang-Jairaj J, Midwinter DA, Rubin DB, Scott-Wilson CA, Crim C.
    Int J Chron Obstruct Pulmon Dis; 2017 Jan 18; 12():351-365. PubMed ID: 28176907
    [Abstract] [Full Text] [Related]

  • 15. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
    Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, Martinez F, Yates J, Newby DE, SUMMIT Investigators.
    Lancet; 2016 Apr 30; 387(10030):1817-26. PubMed ID: 27203508
    [Abstract] [Full Text] [Related]

  • 16. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
    Bollmeier SG, Prosser TR.
    Ann Pharmacother; 2014 Feb 30; 48(2):250-7. PubMed ID: 24259654
    [Abstract] [Full Text] [Related]

  • 17. The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease.
    Bakerly ND, Woodcock A, New JP, Gibson JM, Wu W, Leather D, Vestbo J.
    Respir Res; 2015 Sep 04; 16(1):101. PubMed ID: 26337978
    [Abstract] [Full Text] [Related]

  • 18. The impact of fluticasone furoate/vilanterol on healthcare resource utilisation in the Salford Lung Study in chronic obstructive pulmonary disease.
    Bakerly ND, Browning D, Boucot I, Crawford J, McCorkindale S, Stein N, New JP.
    Ther Adv Respir Dis; 2021 Sep 04; 15():17534666211001013. PubMed ID: 33781142
    [No Abstract] [Full Text] [Related]

  • 19. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease.
    Matera MG, Capuano A, Cazzola M.
    Expert Rev Respir Med; 2015 Feb 04; 9(1):5-12. PubMed ID: 25482512
    [Abstract] [Full Text] [Related]

  • 20. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
    Hanania NA, Mannino DM, Criner GJ, Dransfield MT, Han MK, Jones CE, Kilbride S, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Halpin DMG, Lima R, Lipson DA.
    Chest; 2021 Mar 04; 159(3):985-995. PubMed ID: 33031829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.